The NOP receptor, a target of the endogenous peptide nociceptin/orphanin FQ, is a G-protein-coupled receptor involved in several biological functions, including the modulation of pain, anxiety, sleep-wake rhythm, depression, and motor function. In this work, linear and cyclic derivatives of the minimal active sequence of N/OFQ, N/OFQ(1‑13)‑NH₂, were pharmacologically characterized to evaluate their propensity to stimulate coupling to G protein and β‑Arrestin, two partially separate transduction mechanisms and potentially able to mediate different biological effects. The compounds were characterized by resonance light transfer (BRET) assays on cell lines stably expressing the NOP/protein G and NOP/β‑Arrestin2 constructs, determining the parameters of potency (pEC50) and efficacy (Emax) compared to the reference ligand, and finally calculating the bias factor parameter, a useful measure to quantify the degree of separation in the activation of the two transduction pathways. Cyclization of the peptide chain in several cases preserved the pharmacological profile of the reference compound, while specific chemical modifications of the linear derivatives, with particular impact of substitutions at positions 6 and 7, induced a significant functional bias in favor of activation of the G protein pathway. These results led to the identification of novel peptide ligands for NOP and support functional selectivity as a promising pharmacological strategy for the development of targeted therapeutic agents with possible improved safety profiles.
Il recettore NOP, bersaglio del peptide endogeno nocicettina/orfanina FQ, è un recettore accoppiato a proteine G coinvolto in diverse funzioni biologiche, tra cui la modulazione di dolore, ansia, ritmo sonno veglia, depressione e funzione motoria. In questo lavoro sono stati caratterizzati farmacologicamente derivati lineari e ciclici della minima sequenza attiva di N/OFQ, N/OFQ(1‑13)‑NH₂, per valutare la loro propensione a stimolare l’accoppiamento alla proteina G e alla β‑Arrestina, due meccanismi di trasduzione parzialmente separati e potenzialmente in grado di mediare effetti biologici diversi. I composti sono stati caratterizzati mediante saggi di trasferimento di luce per risonanza (BRET) su linee cellulari stabilmente esprimenti i costrutti NOP/proteina G e NOP/β‑Arrestina2, determinando i parametri di potenza (pEC50) ed efficacia (Emax) rispetto al ligando di riferimento, ed infine calcolando il parametro bias factor, una misura utile a quantificare il grado di separazione nell’attivazione delle due vie trasduzionali. La ciclizzazione della catena peptidica ha in diversi casi preservato il profilo farmacologico del composto di riferimento, mentre specifiche modificazioni chimiche dei derivati lineari, con particolare impatto delle sostituzioni nelle posizioni 6 e 7, hanno indotto un bias funzionale significativo a favore dell’attivazione della via della proteina G. Questi risultati hanno portato all’identificazione di nuovi ligandi peptidici per NOP e supportano la selettività funzionale come strategia farmacologica promettente per lo sviluppo di agenti terapeutici mirati e con possibili profili di sicurezza migliorati.
Valutazione farmacologica in vitro dell’interazione NOP–G proteina e β-Arrestina2 di derivati lineari e ciclici di N/OFQ(1-13)-NH₂
CAROLLO, EMMA
2025/2026
Abstract
The NOP receptor, a target of the endogenous peptide nociceptin/orphanin FQ, is a G-protein-coupled receptor involved in several biological functions, including the modulation of pain, anxiety, sleep-wake rhythm, depression, and motor function. In this work, linear and cyclic derivatives of the minimal active sequence of N/OFQ, N/OFQ(1‑13)‑NH₂, were pharmacologically characterized to evaluate their propensity to stimulate coupling to G protein and β‑Arrestin, two partially separate transduction mechanisms and potentially able to mediate different biological effects. The compounds were characterized by resonance light transfer (BRET) assays on cell lines stably expressing the NOP/protein G and NOP/β‑Arrestin2 constructs, determining the parameters of potency (pEC50) and efficacy (Emax) compared to the reference ligand, and finally calculating the bias factor parameter, a useful measure to quantify the degree of separation in the activation of the two transduction pathways. Cyclization of the peptide chain in several cases preserved the pharmacological profile of the reference compound, while specific chemical modifications of the linear derivatives, with particular impact of substitutions at positions 6 and 7, induced a significant functional bias in favor of activation of the G protein pathway. These results led to the identification of novel peptide ligands for NOP and support functional selectivity as a promising pharmacological strategy for the development of targeted therapeutic agents with possible improved safety profiles.| File | Dimensione | Formato | |
|---|---|---|---|
|
Carollo_Emma.pdf
Accesso riservato
Dimensione
3.19 MB
Formato
Adobe PDF
|
3.19 MB | Adobe PDF |
The text of this website © Università degli studi di Padova. Full Text are published under a non-exclusive license. Metadata are under a CC0 License
https://hdl.handle.net/20.500.12608/118513